[Image from unsplash.com]
1. Biomerics opening new corporate HQ
Biomerics announced in a May 1 press release that it is moving its corporate headquarters in Salt Lake City. The new facility will be 230,000 sq. ft and will be located in the International Center. It will have corporate offices, engineering offices, research and development labs and cleanroom manufacturing. Biomerics is expected to invest $38.5 million in the expansion and add more than 380 jobs over the next 8 years. It is expected to be completed during the second quarter of 2018 and plans to be FDA and ISO-13485 registered for medical device manufacturing.
2. Refocus completes 1-year follow-up for clinical trial
Refocus Group announced in a May 4 press release that it has successfully completed a 12-month follow-up on the 360 patients in its VisAbility Micro-Insert System for presbyopia clinical trial. The next step for Refocus will be preparing for Pre-Market Approval submission to the FDA. The VisAbility Micro-Insert System is the first presbyopic procedure performed outside the line-of-sight of the eyes that is designed to restore vision without the potential of compromising distance vision or depth perception.
3. Glytec touts study
Glytec’s eGlycemic Management System study results show that the system has a 19% reduction in average daily blood glucose between admission and discharge, according to a May 4 press release. The eGlycemic Management System allows hospitals to achieve the basal bolus standard of care for subcutaneous insulin therapy. The study also showed that there was 0% severe hypoglycemia while receiving the target blood glucose of 140-180 mg/dL at every meal and bedtime. Glycemic data from 1,687 non-critically ill patients treated with subcutaneous insulin therapy between July 2016 and January 2017 were used in this study. It was presented at the American Association of Clinical Endocrinologists 26th Annual Scientific Clinical Congress.
